Pierre Lapalme

Filings by Pierre Lapalme span 3 companies, the busiest being Biomarin Pharmaceutical Inc, First Horizon Pharmaceutical Corp and Insys Therapeutics, Inc. Between 25 April 2004 and 4 March 2019, the trades on record add up to 84 filings.

On the open market, the record shows 15 purchases worth €183k and 43 sales worth €4.7M. Netting one side against the other leaves €4.5M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 16 share grants and 10 option exercises.

In size, the median ticket on the buying side is €13k. Looking at 8 purchases old enough to measure, the stock rose over the following 90 days in 13% of cases; the median change was -4.3%. They describe history only and say nothing certain about the share price ahead.

The record was last updated on 23 April 2019 with a share grant in Insys Therapeutics, Inc. The clock since the last published purchase (28 May 2013) now reads 4,896 days. Typically, a trade is published a median of 4 days after it takes place. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.